drugset / Trial / NCT01407003

Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Assessment of LIK066 in Healthy Subjects and in Patients With Type 2 Diabetes Mellitus (T2DM)

NCT01407003

Phase 1/2 Completed 138 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupDouble-blindOther

Summary

This study will assess safety, tolerability, and effect of LIK066 on blood glucose in healthy subjects and in patients with T2DM.

Timeline

Start
2011-06
Primary completion
2013-02
Completion
2013-02

Drugs

EvaluationDrugModalityDoseRoute
Subject licogliflozin Small molecule